Jue Lee - Sinovac Biotech Independent Director
Director
Mr. Jue Lee is Independent Director of Sinovac Biotech Ltd. since May 2011. He is a Principal at SAIF Partners, growth VC funds focused on China. SAIF Partners IV L.P. is a shareholder in Sinovac Biotech Ltd. Mr. Lee has more than 15 years of experience across private equity investment, corporate finance, and business development in China. Before becoming a member of the SAIF team in 2007, he had served as the Chief Financial Officer of Topsec Holdings from 2006 to 2007. From 2004 to 2005, he worked as a Principal at RimAsia Capital Partners. Prior to RimAsia Capital Partners, Mr. Lee served in various positions at Delta Associates, the exclusive advisor to Asia Equity Infrastructure Fund, CNK Telecommunications Limited, HQ Asia Pacific, and Salomon Brothers Inc. in New York. Currently, he is a nonexecutive director on the boards of Yayi International Inc. and China Hanking Holdings Limited since 2012.
| Age | 49 |
| Tenure | 12 years |
| Phone | 86 10 8289 0088 |
| Web | http://www.sinovacbio.com |
Sinovac Biotech Management Efficiency
The company has Return on Asset of 4.53 % which means that on every $100 spent on assets, it made $4.53 of profit. This is considered to be average in the sector. In the same way, it shows a return on shareholders' equity (ROE) of 11.03 %, implying that it generated $11.03 on every 100 dollars invested. Sinovac Biotech's management efficiency ratios could be used to measure how well Sinovac Biotech manages its routine affairs as well as how well it operates its assets and liabilities.The company has 93.13 M in debt with debt to equity (D/E) ratio of 0.28, which may show that the company is not taking advantage of profits from borrowing. Sinovac Biotech has a current ratio of 2.92, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Sinovac Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Sinovac Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sinovac Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sinovac to invest in growth at high rates of return. When we think about Sinovac Biotech's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Matthew Fust | Crinetics Pharmaceuticals | 53 | |
| Kristine Yaffe | Alector | N/A | |
| Roger Loeb | Instil Bio | N/A | |
| Wayne Kauth | Instil Bio | 79 | |
| Gerard Ber | Y mAbs Therapeutics | 60 | |
| James Healy | Y mAbs Therapeutics | 53 | |
| Manisha Pai | Bluebird bio | N/A | |
| Patricia Tilton | Instil Bio | N/A | |
| Aloke Banerjee | Instil Bio | 61 | |
| Cheryl Morley | Cerevel Therapeutics Holdings | 59 | |
| Diana MD | Zentalis PharmaceuticalsLlc | 61 | |
| David Gill | Y mAbs Therapeutics | 63 | |
| Elizabeth Pingpank | Bluebird bio | N/A | |
| Susan Mahony | Assembly Biosciences | 52 | |
| Robert Goldberg | Cerevel Therapeutics Holdings | 69 | |
| Edward Kaye | Cytokinetics | 69 | |
| Jonathan Silverstein | Ascendis Pharma AS | 49 | |
| Frank Thomas | Spero Therapeutics | 47 | |
| Veena Hingarh | Instil Bio | N/A | |
| James Healy | Ascendis Pharma AS | 53 | |
| Rafaele Tordjman | Ascendis Pharma AS | 45 | |
Management Performance
| Return On Equity | 11.03 | ||||
| Return On Asset | 4.53 |
Sinovac Biotech Leadership Team
Elected by the shareholders, the Sinovac Biotech's board of directors comprises two types of representatives: Sinovac Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sinovac. The board's role is to monitor Sinovac Biotech's management team and ensure that shareholders' interests are well served. Sinovac Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sinovac Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Weidong Yin, Chairman, CEO and President Managing Director, Secretary, Chairman of Sinovac Hong Kong, Chairman of Tangshan Yian, Chairman of Sinovac Dalian and Director of Sinovac Biotech Co | ||
| Meng Mei, Independent Director | ||
| Pengfei Li, Director | ||
| Simon Anderson, Independent Director | ||
| Shan Fu, Independent Director | ||
| Stephanie Carrington, IR Contact Officer | ||
| Guowei Wang, Director | ||
| Nan Wang, CFO and VP of Bus. Devel. | ||
| Fung Hoi, Director | ||
| Jing Li, Vice President Quality and Production | ||
| Helen Yang, IR Contact Officer | ||
| Yuk Lo, Independent Director | ||
| Jue Lee, Independent Director | ||
| Xiaomei Yin, Vice President Sales and Marketing | ||
| Jianzeng Cao, Director | ||
| Qiang Gao, Vice President Research and Development | ||
| Ming Xia, VP of Sales and Marketing |
Sinovac Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sinovac Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 11.03 | ||||
| Return On Asset | 4.53 | ||||
| Profit Margin | 10.02 % | ||||
| Operating Margin | 15.86 % | ||||
| Current Valuation | 614.58 M | ||||
| Shares Outstanding | 98.9 M | ||||
| Shares Owned By Insiders | 15.89 % | ||||
| Shares Owned By Institutions | 23.11 % | ||||
| Number Of Shares Shorted | 199.77 K | ||||
| Price To Earning | 48.65 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Other Consideration for investing in Sinovac Stock
If you are still planning to invest in Sinovac Biotech check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sinovac Biotech's history and understand the potential risks before investing.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |